Brokerages expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to post ($0.06) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.04). AVEO Pharmaceuticals posted earnings of ($0.03) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 100%. The company is expected to announce its next earnings results on Thursday, March 12th.
On average, analysts expect that AVEO Pharmaceuticals will report full-year earnings of $0.03 per share for the current financial year, with EPS estimates ranging from $0.00 to $0.06. For the next year, analysts forecast that the company will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.19) to ($0.12). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.09. The business had revenue of $25.72 million during the quarter. AVEO Pharmaceuticals had a net margin of 120.85% and a negative return on equity of 561.43%.
AVEO traded down $0.02 on Tuesday, hitting $0.74. The company had a trading volume of 1,682,662 shares, compared to its average volume of 4,049,819. The business’s fifty day simple moving average is $0.74 and its 200 day simple moving average is $0.74. The company has a quick ratio of 2.87, a current ratio of 2.87 and a debt-to-equity ratio of 0.46. AVEO Pharmaceuticals has a 12-month low of $0.47 and a 12-month high of $2.14. The company has a market cap of $118.95 million, a PE ratio of -3.89 and a beta of 0.71.
In other news, CEO Michael P. Bailey purchased 150,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were bought at an average cost of $0.60 per share, for a total transaction of $90,000.00. Following the acquisition, the chief executive officer now owns 318,848 shares of the company’s stock, valued at approximately $191,308.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.80% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in AVEO Pharmaceuticals by 26.7% during the 2nd quarter. Vanguard Group Inc. now owns 7,670,096 shares of the biopharmaceutical company’s stock valued at $5,164,000 after buying an additional 1,614,802 shares in the last quarter. Cetera Advisor Networks LLC purchased a new position in shares of AVEO Pharmaceuticals during the second quarter worth approximately $38,000. Morgan Stanley raised its stake in shares of AVEO Pharmaceuticals by 265.4% during the second quarter. Morgan Stanley now owns 399,742 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 290,354 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at approximately $98,000. Finally, NEA Management Company LLC raised its stake in shares of AVEO Pharmaceuticals by 20.8% during the second quarter. NEA Management Company LLC now owns 25,243,865 shares of the biopharmaceutical company’s stock valued at $16,913,000 after acquiring an additional 4,347,827 shares in the last quarter. 26.54% of the stock is owned by hedge funds and other institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Further Reading: What are the qualifications of a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.